

type of report	Current report
number	89/2012
company	PHARMENA

Filing a prospectus with Polish Financial Supervision Authority (KNF)

The Management Board of PHARMENA S.A. informs that on 20th December 2012, a prospectus in connection with the planned public offering of series D shares with pre-emptive rights was filed to Polish Financial Supervision Authority (KNF).

The goal of the issue of series D shares is to obtain funds for clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of phase II ("Proof of Concept").
The public offering of series D shares is planned for Q1 2013.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board